Xenon Pharmaceuticals Inc. (XENE)
| Market Cap | 5.46B +86.6% |
| Revenue (ttm) | n/a |
| Net Income | -383.17M |
| EPS | -4.71 |
| Shares Out | 96.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 920,547 |
| Open | 56.13 |
| Previous Close | 56.00 |
| Day's Range | 55.73 - 57.47 |
| 52-Week Range | 28.19 - 63.95 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 70.55 (+25.0%) |
| Earnings Date | May 7, 2026 |
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $70.55, which is an increase of 25.00% from the latest price.
News
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
Needham analyst Serge Belanger lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $78 from $80 and keeps a Buy rating on the shares.
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
“In the first quarter of 2026, we announced positive results from our X-TOLE2 study, which exceeded expectations and reinforced azetukalner’s significant potential to provide a new therapeutic option ...
Xenon Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw strong clinical and financial progress, with AZK's phase III data exceeding expectations and a $747.5M financing extending cash runway into 2029. NDA submission for AZK is planned for Q3 2026, with commercial and pipeline readiness advancing.
Xenon Reports Q1 2026 Financial Results and Provides Business Update
VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, cl...
Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026
Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, cl...
Xenon to Report Q1 2026 Financial Results on May 7, 2026
VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
Azetukalner demonstrated best-in-class efficacy and rapid onset in phase III epilepsy trials, with long-term data showing sustained seizure reduction and strong safety. Expansion into psychiatry and pain indications is underway, supported by robust financials and a growing pipeline.
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
Xenon Pharmaceuticals (XENE) presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures at the American Academy of Neurology Ann...
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-te...
Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
Wedbush lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $63 from $64 and keeps an Outperform rating on the shares. Following completion of the upsized $748M secondary offering,
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Blair acted as joint book running
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clin...
Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
Wedbush raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $64 from $47 and keeps an Outperform rating on the shares. The much-anticipated XTOLE2 Phase 3 data for azetukalner
Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
Guggenheim raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $90 from $60 and keeps a Buy rating on the shares after the company announced topline results from the
Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo
Wells Fargo raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $68 from $49 and keeps an Overweight rating on the shares. The firm says X-TOLE2 data looks good,
Biohaven price target raised to $27 from $24 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Biohaven (BHVN) to $27 from $24 and keeps a Buy rating on the shares. Xenon (XENE) reported strong Phase 3 X-TOLE2 results
Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $75 from $52 and keeps a Buy rating on the shares. Following positive Phase 3 X-TOLE2 results, Xenon
Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $74 from $53 and keeps a Buy rating on the shares following the Phase 3 data for azetukalner.
Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $90 from $56 and keeps a Buy rating on the shares. The company reported “strongly positive” data from
Xenon Pharmaceuticals announces $500M common shares offering
Xenon Pharmaceuticals (XENE) announced that it has commenced an underwritten public offering of $500M of its common shares, pursuant to its existing shelf registration statement. All of the common sha...
Xenon Pharmaceuticals Announces Proposed Public Offering
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...